Endomimetics and BISCO Collaborating to Fund Bionanomatrix Technology

English

简体中文 繁體中文 English Filipino हिन्दी Hmong Bahasa Indonesia 日本語 Basa Jawa 한국어 ພາສາລາວ Bahasa Melayu മലയാളം ဗမာစာ سنڌي தமிழ் ไทย Tiếng Việt Afrikaans Shqip العربية አማርኛ Հայերեն Azərbaycan dili Euskara Беларуская мова বাংলা Bosanski Български Català Cebuano Chichewa Corsu Italiano Hrvatski Čeština‎ Dansk Nederlands Esperanto Eesti Suomi Frysk Galego ქართული Ελληνικά ગુજરાતી Kreyol ayisyen Deutsch Français Harshen Hausa Ōlelo Hawaiʻi עִבְרִית Magyar Íslenska Igbo Gaeilge ಕನ್ನಡ Қазақ тілі ភាសាខ្មែរ كوردی‎ Кыргызча Latin Latviešu valoda Lietuvių kalba Lëtzebuergesch Македонски јазик Malagasy Maltese Te Reo Māori मराठी Монгол नेपाली Norsk bokmål پښتو فارسی Polski Português ਪੰਜਾਬੀ Română Русский Samoan Gàidhlig Српски језик Sesotho Shona සිංහල Slovenčina Slovenščina Afsoomaali Español Basa Sunda Kiswahili Svenska Тоҷикӣ తెలుగు Türkçe Українська اردو O‘zbekcha Cymraeg isiXhosa יידיש Yorùbá Zulu

Endomimetics, a privately held company developing applications for its proprietary Bionanomatrix technology, has announced a collaboration with BISCO to support the development of a dental application for the Bionanomatrix technology. The collaboration will provide $350,000 USD in funding, matching an Alabama Research and Development Enhancement Fund (ARDEF) grant, to support the development of a novel bioactive Direct Pulp Capping (DPC) material using the Bionanomatrix technology. The total funding of $700,000 USD will be used to develop a more effective treatment for dental caries and other dental ailments.

Developing a novel DPC Material

The project will be conducted in the laboratory of Kyounga Cheon, Associate Professor of Dentistry, Department of Pediatric Dentistry, University of Alabama, Birmingham (UAB). Dr. Cheon will lead the development of the novel bioactive DPC material, which is expected to improve dental care and offer a more effective treatment for dental caries and other dental ailments.

Conventional DPC materials have shown limitations in their clinical utility. They have high solubility, low sealing capacity, weak physical properties, uncontrolled pulp necrosis, and unpredictable clinical success. Recent bioceramic materials have been developed to improve clinical outcomes with moderate clinical success, but the bioactive function to induce the formation of a mineralized barrier without pulp necrosis, antimicrobial/anti-inflammatory capacity, physical-mechanical properties, and cost-effectiveness of these DPC materials still need improvement. The project focuses on developing a novel DPC material by improving bioactivity of pulp tissue while achieving ideal mechanical properties.

Collaborating with BISCO

The collaboration with BISCO is part of Endomimetics’ core strategy to develop candidate applications of the Bionanomatrix and partner with industry leaders to advance those candidates through clinical development and, if successful, to patients.

“The matching funds provided by Endomimetics and BISCO for Dr. Cheon’s ARDEF grant will provide additional support for her research and, hopefully, result in a viable product candidate to improve dental care.” said Joseph Garner, CEO of Endomimetics.

The ARDEF was established by the Alabama Innovation Act (AIA) and is administered by Alabama Department of Economic and Community Affairs (ADECA) to encourage new and continuing efforts to conduct research and development activities within Alabama. The development of the bioactive DPC began in early 2023 and is expected to run for two years. With the additional funding from Endomimetics and BISCO, Dr. Cheon’s research can advance more rapidly and potentially bring a much-needed breakthrough in dental care.